Leeds submit planning application for Elland Road expansion
After several months of public consultation, the club is satisfied with a 98 per cent approval rating from those who responded to their questionnaire at their exhibitions of the plans.
Advertisement
In the first phase of their plans, Leeds want to expand the John Charles Stand from a capacity of 8,000 to 17,750. This application includes a detailed plan for the first phase and an outline of their intentions for the Don Revie Stand in the longer term.
Leeds chief business officer Morrie Eisenberg said: 'We are delighted to submit a planning application to Leeds City Council on schedule with our proposed timeline of the project. This is a result of the hard work of everyone involved over the past 18 months, where designs and concepts have been developed to revitalise Elland Road, while preserving the unique history and heritage it holds.
'I would like to thank everyone who took the time to go to the public exhibition at the Centenary Pavilion and the consultation sessions in the local community, with over 1,800 people visiting in person, and those who completed the questionnaire and provided us with invaluable comments and feedback, which have all been considered.
'As a club, we believe this development will provide great economic benefits to the local community and will be a catalyst for a regeneration of the area.'
According to a statement from Leeds, 97 per cent of questionnaire respondents supported an increase in capacity, 98 per cent supported the design plans and 99 per cent supported the economic benefits the redevelopment will deliver.
A final decision on the application is expected within 13 weeks, which is October 7.
()
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
an hour ago
- Bloomberg
Virgin Atlantic Will Use Musk's Starlink for Wi-Fi Across Fleet
Virgin Atlantic Airways announced a deal with SpaceX's Starlink to overhaul the onboard Wi-Fi across its entire fleet, making it the first UK carrier to strike a deal with Elon Musk's company. The British long-haul carrier will start installing Starlink on its aircraft next year and expects to finish the full retrofit by the end of 2027.
Washington Post
an hour ago
- Washington Post
Aryna Sabalenka, Taylor Fritz take different paths to Wimbledon semifinals
WIMBLEDON, England — There may be no better preparation for winning a grass-court tournament than playing a wily, determined, 37-year-old doubles aficionado with a special place in her heart for the slice. Except, perhaps, than facing a British darling on Center Court at Wimbledon in front of a crowd so loud it rivaled some of Andy Murray's matches.
Associated Press
an hour ago
- Associated Press
Plexāā Closes $4.5 Million Funding Extension to Drive U.S. Launch of BLOOM43 Platform for Breast Surgery
LONDON--(BUSINESS WIRE)--Jul 8, 2025-- Plexāā, a MedTech startup behind the award-winning BLOOM 43 medical device for breast surgery, has announced the close of a $4.5 million funding extension round. The strategic capital infusion will support the imminent U.S. launch of BLOOM 43, while also laying the groundwork for future innovations. The funding also strengthens the company's position ahead of their planned Series A fundraising round. Complication rates in breast surgeries, which can include infection, skin necrosis and the need for additional surgeries, have been recorded as high as 30 percent. 1 BLOOM 43 is the world's first fully wearable medical device designed to help patients prepare for breast cancer surgery and reconstruction by harnessing the power of Supraphysiological Preconditioning ™. The new technique safely and intermittently thermally preconditions the skin causing the release of heat-shock proteins that cause vasodilation and increased blood flow to the area. This process has been shown to reduce wound healing complications in proof-of-concept clinical trials. Along with its BLOOM 43 companion app, the device has demonstrated substantial improvements in the patient experience and surgical readiness, harnessing the power of holistic Prehabilitation ™ and preconditioning. The company has already secured multiple partners for its upcoming U.S. commercial launch. 'I want to thank our team for the tremendous progress it has made to make this financing possible,' said Dr. Saahil Mehta, founder and CEO of Plexāā. 'Securing this funding validates confidence in our flagship technology and the concept of Supraphysiological Preconditioning ™, and it energizes the team as we prepare to bring BLOOM 43 to a wider patient population in the U.S. and beyond. The funds will support this pivotal launch and market expansion, as well as the exciting development of our technology platform – including devices and apps targeting additional surgical specialties and creating a whole new category in surgery.' Plexāā Ltd has been backed by TCP Health Ventures (the dedicated healthcare investment arm of The Capital Partnership group of companies) who led the Seed Round. This extension round comprises existing and new investors including TCP. Further investment includes over $1.6 million in i4i grant funding from the National Institute for Health and Care Research (NIHR), and $1.3 million from Thena Capital, a London-based VC firm backed by the British Business Bank and focused on digital health and fast-tracked Medtech. Tatum Getty, founding General Partner at THENA Capital added, 'Since 2023, we've been closely tracking Plexāā's progress and the development of its first device, BLOOM 43. We couldn't be more excited for Plexāā to become our first portfolio company for THENA Capital's Fund I. The company is solving a critical and under-addressed challenge across the surgical pathway- reducing post-operative complications for patients which also addresses the impact to both providers and payers. 'Saahil and his team bring together clinical, engineering, and operational expertise from some of the UK's leading institutions. Their bold ambition to scale globally, beginning with an imminent commercial launch in the U.S., is exactly the kind of UK MedTech leadership team we look to champion. Our fund's commercialisation support model is well-suited to help Plexāā expand into women's health and adjacent categories where better outcomes and patient experiences are urgently needed.' Plexāā plans to collaborate with clinicians, patients, and partners worldwide to make prehabilitation and preconditioning the standard of care for surgery — and to deliver transformative solutions that address unmet needs in surgical care. About Plexāā Plexāā is a pioneering UK-based MedTech company focused on improving surgical outcomes through devices and digital products. Its flagship device, BLOOM 43, enables patients to supraphysiologically precondition their skin, potentially reducing the risk of wound healing complications such as infection and skin necrosis, which affect one in three women undergoing breast surgery. Plexāā is also exploring the application of this technology in other surgical fields, including obstetrics for C-sections, orthopaedics for joint operations, and general and vascular surgery, with a commitment to improving pre-operative preparation for surgery and patient outcomes. About TCP Health Ventures TCP Health Ventures is the dedicated healthcare investment arm of The Capital Partnership group of companies, a multi-asset investment company with assets under management of $7 billion. Headquartered out of London, TCP Health Ventures manages assets of $ 225 million across 15+ investments in the med-tech space and has a med-tech investing experience of 10 years. About the NIHR The mission of the National Institute for Health and Care Research (NIHR) is to improve the health and wealth of the nation through research. We do this by: NIHR is funded by the Department of Health and Social Care. Its work in low- and middle- income countries is principally funded through UK international development funding from the UK government. About THENA Capital THENA Capital is a London-based venture capital firm backing the world's next category-defining medical technologies. We invest in breakthrough companies transforming care experiences through digital health, fast-tracked medical devices, and clinical-grade innovation. THENA's debut Fund 1, focuses on high-impact, UK-founded technologies addressing unmet needs across women's health, oncology, cardiovascular disease, chronic conditions, and care delivery. With deep clinical, regulatory and operational expertise, THENA Capital partners with founders to unlock international scale, navigate complex markets, and build enduring category leaders in global healthcare. References 1 Annals of Translational Medicine, Dec 2023, Management of complications following implant-based breast reconstruction: a narrative review, Dean H. Meshkin 1^, Joseph M. Firriolo 1, Nolan S. Karp 2, Ara A. Salibian 1 View source version on CONTACT: Media Contacts: Sam Choinski Pazanga Health Communications [email protected] (860) 301-5058 [email protected] KEYWORD: EUROPE UNITED STATES UNITED KINGDOM NORTH AMERICA NEW YORK INDUSTRY KEYWORD: TECHNOLOGY BIOTECHNOLOGY HEALTH CONSUMER APPS/APPLICATIONS SURGERY PROFESSIONAL SERVICES ONCOLOGY MEDICAL DEVICES SOFTWARE DATA ANALYTICS HEALTH TECHNOLOGY WOMEN DATA MANAGEMENT SOURCE: Plexāā Copyright Business Wire 2025. PUB: 07/08/2025 03:46 PM/DISC: 07/08/2025 03:46 PM
